Active ingredients through manufacturing, distribution, and insurance to the patient, and the handful of firms the whole system cannot route around.
The value chain
How value flows, top to bottom
This is a supply chain, not an ownership chart. Tap any layer to see its companies.
No companies match those filters.
Five-year income-statement trends for the chokepoints. Revenue bars read on the left; margins read on the right. Most chokepoints here are SEC filers or major public companies on developed exchanges, so expect solid source tiers on accounting data.
The value chain
Nine layers, one flow
Each layer sells to the one below it. Tap a layer to jump to its companies.
From
Relationship
To
What
Confidence
No relationships match.
The companies the rest of the chain has the fewest alternatives to. Drug originators and generic makers are comparatively diverse; the API layer, sterile manufacturing, physical distribution, and insurance administration are where routing options run out. Every call here is a foundation hypothesis until relationship edges test it.
Evidence
What the filings won't say
Every edge on this map is sourced. That is a rule about what the map may
claim, not a claim about what exists. These are the things we went looking for and could
not source, each one recorded with the documents actually read to establish it, and with what
would close it. An absence that names where it looked can be checked. One that does not is a shrug,
so the gate refuses to accept it.
No gaps recorded yet. This map has not run a
research burst, so it has nothing to say about what it could not find.
Every figure in this map traces to a primary source. Links open the original filing.
Your data
Watchlist and notes
Your stars and notes live only in this browser. Export them to keep a real backup.
Watchlist
All notes
A place for what you are learning as the map grows.